Corriu C, Bernard S, Schott C, Stoclet J C
Université Louis Pasteur de Strasbourg, Laboratoire de Pharmacologie Cellulaire et Moléculaire, Illkirch, France.
J Cardiovasc Pharmacol. 1995 Nov;26(5):688-92. doi: 10.1097/00005344-199511000-00003.
We investigated the selectivity of losartan as an angiotensin II (ANG II) antagonist in contractile experiments using segments of small mesenteric arteries and rings of aorta from rat. The concentration-effect curve of ANG II was not different in mesenteric arteries with an without endothelium. In both resistance and conductance vessels, it was shifted toward larger concentrations by losartan (3 nM) with similar apparent inhibition constant (KB) values: 4.1 +/- 1.8 nM (n = 6) in small mesenteric arteries and 1.9 nM (n = 6) in aorta. These values agree with the known affinity of losartan for AT1 receptors. At 1 microM, the AT2-selective ligand CGP 42112A had no effect on contractile responses induced by norepinephrine (NE), serotonin, or neuropeptide Y (NPY). However, it inhibited vasoconstriction elicited by prostaglandin F2 alpha (PGF2 alpha). This latter effect was also noted in the aorta. Similarly, losartan also competitively antagonized aortic contractile responses elicited by U 46619, a thromboxane A2 analogue (TXA2), with a pA2 value of 5.7. Two losartan analogues, DuP 532 and EXP 3174 (a metabolite of losartan), < or = 30 microM, did not antagonize U 46619, showing structural requirements for this antagonistic action of losartan. We conclude that in both rat resistance and conductance vessels, ANG II induces vasoconstriction through activation of AT1 receptors which are selectively blocked by losartan at nanomolar concentrations and that at micromolar concentrations, losartan may also block the vascular TXA2/PGF2 alpha (TP) receptor.
我们在使用大鼠小肠系膜动脉节段和主动脉环的收缩实验中,研究了氯沙坦作为血管紧张素II(ANG II)拮抗剂的选择性。有无内皮的肠系膜动脉中,ANG II的浓度-效应曲线并无差异。在阻力血管和传导血管中,氯沙坦(3 nM)均使浓度-效应曲线向更高浓度偏移,其表观抑制常数(KB)值相似:小肠系膜动脉中为4.1±1.8 nM(n = 6),主动脉中为1.9 nM(n = 6)。这些值与氯沙坦对AT1受体的已知亲和力相符。在1 microM时,AT2选择性配体CGP 42112A对去甲肾上腺素(NE)、5-羟色胺或神经肽Y(NPY)诱导的收缩反应无影响。然而,它抑制了前列腺素F2α(PGF2α)引起的血管收缩。在主动脉中也观察到了后一种效应。同样,氯沙坦也竞争性拮抗了血栓素A2类似物(TXA2)U 46619引起的主动脉收缩反应,pA2值为5.7。两种氯沙坦类似物,DuP 532和EXP 3174(氯沙坦的一种代谢产物),≤30 microM时,并不拮抗U 46619,表明氯沙坦的这种拮抗作用存在结构要求。我们得出结论,在大鼠阻力血管和传导血管中,ANG II通过激活AT1受体诱导血管收缩,氯沙坦在纳摩尔浓度下可选择性阻断该受体,而在微摩尔浓度下,氯沙坦也可能阻断血管TXA2/PGF2α(TP)受体。